Candidate PET radioligands for cannabinoid CB1 receptors: [ 18F]AM5144 and related pyrazole compounds

Nuclear Medicine and Biology

Volumn 32, Issue 4, 2005, Pages 361-366

  Li, Zizhong ^a   Gifford, Andrew ^a   Liu, Qian ^b   Thotapally, Rajesh ^b   Ding, Yu Shin ^a   Makriyannis, Alexandros ^b   Gatley, S John ^a,b  

^a BROOKHAVEN NATIONAL LABORATORY   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Cannabinoid receptors; Fluorine 18; Lipophilicity; Pyrazole; Radiosynthesis

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 1 FLUORO 4 NITROBENZENE; 4 FLUOROANILINE; AM 5144; ANILINE DERIVATIVE; CANNABINOID 1 RECEPTOR; COBALT CHLORIDE; N (4 FLUOROPHENYL) 5 (4 BROMOPHENYL) 1 (2,4 DICHLOROPHENYL) 1H PYRAZOLE 3 CARBOXAMIDE F 18; NITROBENZENE DERIVATIVE; PYRAZOLE DERIVATIVE; RADIOLIGAND; SODIUM BOROHYDRIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BABOON; CATALYSIS; CONTROLLED STUDY; DRUG PURITY; DRUG RECEPTOR BINDING; DRUG UPTAKE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RADIOCHEMISTRY; REDUCTION;

ANILINE COMPOUNDS; ANIMALS; BRAIN; FEMALE; LIGANDS; METABOLIC CLEARANCE RATE; PAPIO; POSITRON-EMISSION TOMOGRAPHY; PYRAZOLES; RADIOPHARMACEUTICALS; RECEPTOR, CANNABINOID, CB1; TISSUE DISTRIBUTION;

EID: 18944375992     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2005.02.007     Document Type: Article

References (39)

1. W.A. Devane, F.A. Dysarz III, M.R. Johnson, L.S. Melvin, and A.C. Howlett Determination and characterization of a cannabinoid receptor in rat brain Mol Pharmacol 34 1988 605 613
2. W.A. Devane, L. Hanus, A. Breuer, R.G. Pertwee, L.A. Stevenson, and G. Griffin Isolation and structure of a brain constituent that binds to the cannabinoid receptor Science 258 1992 1946 1949
3. 2 receptors Pharmacol Ther 74 1997 129 180
4. B.F. Thomas, D.R. Compton, and B.R. Martin Characterization of the lipophilicity of natural and synthetic analogs of delta 9-tetrahydrocannabinol and its relationship to pharmacological potency J Pharmacol Exp Ther 255 1990 624 630
5. P.H. Reggio Pharmacophores for ligand recognition and activation/inactivation of the cannabinoid receptors Curr Pharm Des 9 2003 1607 1633
6. 1 receptors in vivo J Neurochem 70 1998 417 423
7. 1 selective cannabinoid antagonist AM281: a potential human SPECT ligand AAPS PharmSci 1 1999 E4
8. G. Berding, K. Muller-Vahl, U. Schneider, P. Gielow, J. Fitschen, and M. Stuhrmann [(123)I]AM281 single-photon emission computed tomography imaging of central cannabinoid CB(1) receptors before and after Delta(9)- tetrahydrocannabinol therapy and whole-body scanning for assessment of radiation dose in Tourette patients Biol Psychiatry 55 2004 904 915
9. E.Q. Chen, W.J. MacIntyre, R.T. Go, R.C. Brunken, G.B. Saha, and C.Y. Wong Myocardial viability studies using fluorine-18-FDG SPECT: a comparison with fluorine-18-FDG PET J Nucl Med 38 1997 582 586
10. R. Lan, Q. Liu, P. Fan, S. Lin, S.R. Fernando, and D. McCallion Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists J Med Chem 42 1999 769 776
11. A.J. Leo Some advantages of calculating octanol-water partition coefficients J Pharm Sci 76 1987 166 168
12. 1 receptors Eur J Pharmacol 307 1996 331 338
13. Y.-S. Ding, F. Liang, J.S. Fowler, M.J. Kuhar, and F.I. Carroll Synthesis of [18F]norchlorofluoroepibatidine and its N-methyl derivative: new PET ligands for mapping nicotinic acetylcholine receptors J Label Cmpd Radiopharm 39 1997 827 832
14. 18F-delta 8-THC Pharmacol Biochem Behav 40 1991 503 507
15. J.S. Fowler, N.D. Volkow, A.P. Wolf, S.L. Dewey, D.J. Schlyer, and R.R. Macgregor Mapping cocaine binding sites in human and baboon brain in vivo Synapse 4 1989 371 377
16. 18F-labeled S-aryl-cysteine and a radiolabeled peptide J Label Compd Radiopharm 45 2002 1229 1238
17. Z. Li, Y.S. Ding, A. Gifford, J.S. Fowler, and J.S. Gatley Synthesis of structurally identical fluorine-18 and iodine isotope labeling compounds for comparative imaging Bioconjug Chem 14 2003 287 294
18. M. Herkenham, A.B. Lynn, M.D. Little, M.R. Johnson, L.S. Melvin, and B.R. de Costa Cannabinoid receptor localization in brain Proc Natl Acad Sci U S A 87 1990 1932 1936
19. S.J. Gatley, R. Lan, B. Pyatt, A.N. Gifford, N.D. Volkow, and A. Makriyannis Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors Life Sci 61 1997 PL 191 PL 197
20. 1 cannabinoid receptors J Label Compd Radiopharm 46 2002 93 98
21. 18F] SR147963: selective radioligands for positron emission tomographic studies of brain cannabinoid receptors Nucl Med Biol 27 2000 757 762
22. W.B. Mathews, U. Scheffel, P.A. Rauseo, H.T. Ravert, R.A. Frank, and G.J. Ellames Carbon-11 labeled radioligands for imaging brain cannabinoid receptors Nucl Med Biol 29 2002 671 677
23. 1 receptor antagonist AM251 as a candidate SPECT radioligand Abstr Soc Neurosci 2002
24. Z. Li, Y.S. Ding, J.S. Fowler, Y. XU, C. Shea, and V. Garza Synthesis of fluorine-18 and carbon-11 labeled cannabinoid receptor radioligands for PET studies J Nucl Med 44 2003 293P
25. 35S]thio)-triphosphate binding assay in rat cerebellar membranes J Pharmacol Exp Ther 285 1998 553 560
26. G. Griffin, E.J. Wray, B.R. Martin, and M.E. Abood Cannabinoid agonists and antagonists discriminated by receptor binding in rat cerebellum Br J Pharmacol 128 1999 684 688
27. L. Lay, J.A. Angus, and C.E. Wright Pharmacological characterisation of cannabinoid CB(1) receptors in the rat and mouse Eur J Pharmacol 391 2000 151 161
28. S.J. Gatley, A.N. Gifford, Y.-S. Ding, R. Lan, Q. Liu, and N.D. Volkow Development of PET and SPECT radioligands for cannabinoid receptors A. Makriyannis D. Biegel Drug discovery strategies and methods 2004 Marcel Dekker New York 129 146
29. D.W. Yu, S.J. Gatley, A.P. Wolf, R.R. MacGregor, S.L. Dewey, and J.S. Fowler Synthesis of carbon-11 labeled iodinated cocaine derivatives and their distribution in baboon brain measured using positron emission tomography J Med Chem 35 1992 2178 2183
30. 11C]SA4503, by P-glycoprotein modulation Synapse 48 2003 80 86
31. 18F]MPPF in rats Eur J Pharmacol 407 2000 273 280
32. B.F. Thomas, D.R. Compton, and B.R. Martin Characterization of the lipophilicity of natural and synthetic analogs of delta 9-tetrahydrocannabinol and its relationship to pharmacological potency J Pharmacol Exp Ther 255 1990 624 630
33. A.A. Wilson, L. Jin, A. Garcia, J.N. DaSilva, and S. Houle An admonition when measuring the lipophilicity of radiotracers using counting techniques Appl Radiat Isot 54 2001 203 208
34. H. van de Waterbeemd, D.A. Smith, and B.C. Jones Lipophilicity in PK design: methyl, ethyl, futile J Comput Aided Mol Des 15 2001 273 286
35. R.N. Waterhouse Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents Mol Imaging Biol 5 2003 376 389
36. G.F. Ecker, and C.R. Noe In silico prediction models for blood-brain barrier permeation Curr Med Chem 11 2004 1617 1628
37. T. Arai, S. Wakabayashi, M.A. Channing, B.B. Dunn, M.G. Der, and J.M. Bell Incorporation of [1-carbon-11]palmitate in monkey brain using PET J Nucl Med 36 1995 2261 2267
38. 1-11C]arachidonate in normocapnic and hypercapnic monkeys, measured with positron emission tomography Brain Res 755 1997 74 83
39. 11C]arachidonic acid in young healthy humans measured with positron emission tomography J Cereb Blood Flow Metab 22 2002 1453 1462